Astellas, King Sue Teva Over Adenoscan Patent

Law360, New York (June 1, 2005, 12:00 AM EDT) -- King Pharmaceuticals and a U.S. subsidiary of Japanese drug maker Astellas Pharmaceuticals have jointly filed a lawsuit against Israeli generics maker Teva Pharmaceuticals, accusing the company of infringing King's patent on Adenoscan.

The complaint, filed in the U.S. District Court for the District of Delaware on May 26, seeks a court order prohibiting the FDA's approval of Teva subsidiary Sicor's abbreviated new drug application for a generic version of pharmacologic stress agent Adenoscan (adenosine injection) before the expiration of King's U.S. patent number '877 May 18,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.